PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Sarepta and Catalent expand manufacturing deal ahead of DMD gene therapy approval

Sarepta Therapeutics announced that it has signed a commercial supply agreement with CDMO giant Catalent to manufacture SRP-9001, Sarepta’s most advanced gene therapy candidate for the treatment of Duchenne muscular dystrophy (DMD).

The U.S. FDA accepted Sarepta’s BLA seeking accelerated approval of SRP-9001 for the treatment of ambulant individuals with DMD back in November. The therapy was granted Priority Review and given a regulatory action date of May 29, 2023.

SRP-9001 (delandistrogene moxeparvovec) is an investigational gene therapy for Duchenne being developed in partnership with Roche. Massachusetts-based Sarepta is responsible for global development and manufacturing and plans to commercialize SRP-9001 in the U.S. upon receiving FDA approval. Back in Dec. 2019, Roche handed over $1.15 billion to obtain the rights to the drug outside the U.S.

If approved in May, SRP-9001 will be the first gene therapy for Duchenne — a one-time treatment designed to treat the underlying cause of DMD by delivering a functional shortened dystrophin to muscle tissue.

Catalent’s gene therapy network includes state-of-the-art facilities that currently house 10 CGMP gene therapy manufacturing suites, with another 8 suites under construction, each capable of accommodating multiple bioreactors up to 2,000-liter scale. The agreement with Sarepta also structures how Catalent may support multiple gene therapy candidates in Sarepta’s pipeline for limb-girdle muscular dystrophy (LGMD).

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026